Optimizing the treatment of hypothyroidism

Antonio C. Bianco; Peter N. Taylor

doi:10.1038/s41574-024-00989-7

Optimizing the treatment of hypothyroidism

Antonio C. Bianco^*
, Peter N. Taylor

^*Corresponding author for this work

Immunology and Immunotherapy

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Daily levothyroxine (LT₄) is the standard of care for the treatment of hypothyroidism; however, a small number of patients experience residual symptoms of hypothyroidism. Guidelines indicate that a trial with LT₄ and liothyronine (LT₃) could be attempted once other conditions have been addressed or excluded. Even so, currently, treatment of hypothyroidism can still be suboptimal.

Original language	English
Pages (from-to)	379-380
Number of pages	2
Journal	Nature Reviews Endocrinology
Volume	20
Issue number	7
Early online date	29 Apr 2024
DOIs	https://doi.org/10.1038/s41574-024-00989-7
Publication status	Published - Jul 2024

Bibliographical note

Not in scope.
Publisher Copyright:
© Springer Nature Limited 2024.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1038/s41574-024-00989-7Licence: None: All rights reserved

Cite this

@article{435f429cb206415eb7cb8c508c36c8aa,

title = "Optimizing the treatment of hypothyroidism",

abstract = "Daily levothyroxine (LT4) is the standard of care for the treatment of hypothyroidism; however, a small number of patients experience residual symptoms of hypothyroidism. Guidelines indicate that a trial with LT4 and liothyronine (LT3) could be attempted once other conditions have been addressed or excluded. Even so, currently, treatment of hypothyroidism can still be suboptimal.",

author = "Bianco, \{Antonio C.\} and Taylor, \{Peter N.\}",

note = "Not in scope. Publisher Copyright: {\textcopyright} Springer Nature Limited 2024.",

year = "2024",

month = jul,

doi = "10.1038/s41574-024-00989-7",

language = "English",

volume = "20",

pages = "379--380",

journal = "Nature Reviews Endocrinology",

issn = "1759-5029",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Optimizing the treatment of hypothyroidism

AU - Bianco, Antonio C.

AU - Taylor, Peter N.

PY - 2024/7

Y1 - 2024/7

N2 - Daily levothyroxine (LT4) is the standard of care for the treatment of hypothyroidism; however, a small number of patients experience residual symptoms of hypothyroidism. Guidelines indicate that a trial with LT4 and liothyronine (LT3) could be attempted once other conditions have been addressed or excluded. Even so, currently, treatment of hypothyroidism can still be suboptimal.

AB - Daily levothyroxine (LT4) is the standard of care for the treatment of hypothyroidism; however, a small number of patients experience residual symptoms of hypothyroidism. Guidelines indicate that a trial with LT4 and liothyronine (LT3) could be attempted once other conditions have been addressed or excluded. Even so, currently, treatment of hypothyroidism can still be suboptimal.

UR - https://www.scopus.com/pages/publications/85191753338

U2 - 10.1038/s41574-024-00989-7

DO - 10.1038/s41574-024-00989-7

M3 - Comment/debate

C2 - 38684871

AN - SCOPUS:85191753338

SN - 1759-5029

VL - 20

SP - 379

EP - 380

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

IS - 7

ER -

Optimizing the treatment of hypothyroidism

Abstract

Bibliographical note

UN SDGs

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this